Theophylline: Efficacy in Asthma and COPD

Theophylline (brand names Bronchoretard, Euphylong, Solosin, and generics) is a methylxanthine chemically closely related to caffeine and theobromine. Used in bronchial therapy since the early 20th century, theophylline is now considered a reserve medication for asthma and chronic obstructive pulmonary disease (COPD). Its role has declined significantly since the introduction of modern inhaled substances, yet in selected situations theophylline remains a reasonable option, particularly in patients not adequately controlled with inhaled therapy alone.

Characteristic of theophylline is its narrow therapeutic window, effective plasma levels and toxic concentrations lying close together. This necessitates careful dosing, regular level monitoring, and a thorough understanding of drug interactions. Prescribers can rely on proven efficacy with bronchodilation, respiratory muscle strengthening, and mild anti-inflammatory effect, but must keep safety aspects in view.

Mechanism of Action

Theophylline acts through multiple mechanisms. The primary mechanism is non-selective inhibition of phosphodiesterases (PDE3 and PDE4), which increases intracellular cAMP levels. This results in relaxation of smooth bronchial muscle and thus bronchodilation. Additionally, theophylline antagonizes adenosine receptors A1 and A2, reducing bronchoconstriction from adenosine and exerting a stimulating effect on the central nervous system.

A further effect is the activation of histone deacetylase 2 (HDAC2), which dampens inflammatory gene expression in the lungs. This effect is especially discussed in COPD patients where glucocorticoid sensitivity is limited by oxidative stress. Theophylline also increases respiratory muscle contractility, which can be clinically relevant in respiratory muscle fatigue.

Half-life varies considerably between individuals and is approximately 8 to 10 hours in adults without comorbidity. It is prolonged in liver disease, heart failure, advanced age, and with inhibition of the primary metabolizing enzyme CYP1A2. It is shortened in smokers because tobacco smoke induces CYP1A2. Therapeutic plasma levels range from 8 to 20 micrograms per ml. Values above 20 are associated with increasing adverse effects, values above 30 with serious toxicity.

Indications

• Asthma as a reserve step medication, supplementing inhaled glucocorticoids and long-acting beta 2 agonists, especially for nocturnal symptoms or inadequate symptom control
• Chronic obstructive pulmonary disease (COPD) as add-on in symptomatic patients inadequately controlled with inhaled therapy
• Acute severe asthma exacerbation, intravenously as reserve when beta 2 agonists and systemic glucocorticoids are insufficient
• Apnea of prematurity, in pediatric intensive care as respiratory stimulant therapy
• Bradycardia and sinus node dysfunction in specialized cardiologic settings, very rarely

Theophylline is not first-line for asthma or COPD because inhaled substances are better controllable and have a more favorable adverse effect profile. Theophylline therapy should be managed by experienced pneumologists, internists, or pediatricians.

Dosage and Administration

Adults oral sustained-release: Begin with 200 mg twice daily, increase according to plasma level and tolerability to typically 300 to 400 mg twice daily. Maximum dose individualized, often 800 to 900 mg daily, depending on level.

Acute intravenous: Bolus 5 to 6 mg per kg body weight over 30 minutes, then continuous infusion 0.3 to 0.7 mg per kg body weight per hour. In patients already taking oral theophylline, check level before bolus or reduce bolus to avoid overdose.

Pediatric: Dosage weight-adapted, individual levels are mandatory. In premature infants, lower dosage due to slower metabolism.

Level monitoring: recommended three to five days after therapy initiation or dose change. Earlier with concomitant medication or comorbidity. Target range 8 to 20 micrograms per ml.

Renal insufficiency: generally no dose adjustment required. Liver insufficiency, heart failure, advanced age: significantly reduced dose and close level monitoring because half-life is prolonged. Smokers: often higher doses due to induced metabolism.

Administration: Swallow sustained-release tablets whole with sufficient water, preferably evenly throughout the day. Some preparations should exert their main effect in the morning, others in the evening, depending on the effect profile. Abrupt switching between products from different manufacturers can change levels.

Adverse Effects

At therapeutic range levels: nausea, heartburn, headache, restlessness, insomnia, tremor, tachycardia.

At levels above 20 micrograms per ml: vomiting, diarrhea, hyperactivity, sweating, hypertension, marked tachycardia, hyperreflexia, hypokalemia, and hyperglycemia.

At levels above 30 micrograms per ml: seizures, severe arrhythmias (particularly supraventricular tachycardias, extrasystoles, ventricular tachycardias), circulatory-relevant hypotension, altered consciousness. Severe theophylline toxicity is an intensive care emergency.

Antidote: no specific antidote available. Toxicity treatment is symptomatic with activated charcoal, circulatory stabilization, seizure management with benzodiazepines, hypokalemia correction, and in severe cases hemodialysis for level reduction.

Long-term use: insomnia, irritable stomach, and reflux are common reasons for therapy discontinuation. Adjusting the administration time can help.

Drug Interactions

• CYP1A2 inhibitors such as ciprofloxacin, norfloxacin, fluvoxamine, cimetidine, oral contraceptives, erythromycin, clarithromycin: significant elevation of theophylline levels, risk of toxicity, dose adjustment or avoidance required.
• CYP1A2 inducers such as rifampicin, phenytoin, carbamazepine, phenobarbital, tobacco smoke: decreased levels, often higher doses required.
• Beta 2 agonists (salbutamol, formoterol, salmeterol): additive bronchodilatory effect desired, simultaneously additive tachycardia, tremor, and hypokalemia.
• Glucocorticoids: with theophylline increased hypokalemia tendency, especially with additional beta 2 agonists.
• Diuretics such as furosemide and hydrochlorothiazide: additive hypokalemia, caution in patients with arrhythmia tendency.
• Adenosine: theophylline antagonizes its effect, clinically relevant in adenosine-based cardiac stress tests.
• Allopurinol, disulfiram, methotrexate: CYP inhibition, possible level increase.

Special Notes

Pregnancy: Theophylline is considered applicable with strict indication and close level monitoring. Due to increased clearance in pregnancy, levels may decrease, dose adjustment if necessary. Breast-feeding: Transfer into breast milk, monitor for signs such as restlessness, poor feeding, or tachycardia in the infant.

Children: established in pediatrics, especially for prematurity-related apnea. Level monitoring is mandatory.

Elderly patients: prolonged half-life, comorbidities frequent. Dose reduction and close monitoring are necessary.

Before therapy initiation: History of cardiac disease, seizures, thyroid overfunction, gastroduodenal ulcers. These conditions are critical and may require therapy avoidance or strict monitoring.

Switching products: Theophylline is a classic candidate for generic substitution with pharmacokinetic consequences. When switching between generics or different sustained-release formulations, check levels.

Driving ability: generally preserved, individual assessment with tremor or sleep disorders.

Lifestyle: Tobacco smoke significantly affects efficacy. Patients who stop smoking should have their theophylline level checked because levels can increase within weeks.

You might also be interested in

• Salbutamol, short-acting beta 2 agonist in acute bronchial obstruction
• Formoterol, long-acting beta 2 agonist in maintenance therapy
• Budesonid, inhaled glucocorticoid in asthma and COPD
• Montelukast, leukotriene receptor antagonist in asthma
• Cineol, plant-derived secretolytic in respiratory tract diseases

Frequently Asked Questions

Sources

• Gelbe Liste, Theophylline active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, National Care Guideline Asthma and COPD
• GOLD Initiative, international COPD recommendations